茵栀黄口服液联合更昔洛韦治疗新生儿巨细胞病毒肝炎33例-《西部中医药》

文章信息/Info

Title:: YinZhiHuang Oral Liquid and Ganciclovir in the Treatment for 33 Cases of Neonatal Cytomegalovirus Hepatitis

Author(s):: CHEN Xixiang; Neonatology Department of Yangxin County People′s Hospital, Yangxin 435200, China

Keywords:: cytomegalovirus hepatitis; YinZhiHuang oral liquid; ganciclovir; neonate

摘要:: 目的：观察茵栀黄口服液联合更昔洛韦对新生儿巨细胞病毒（CMV）肝炎的临床疗效。方法：随机将63例CMV肝炎患儿分为2组。2组均采用更昔洛韦注射液治疗，观察组加用茵栀黄口服液，每次1/2支，3次/d。2组均以2周为1个疗程。2组患者常规使用其他保肝药物。结果：丙氨酸转氨酶(ALT)、血清谷草氨转氨酶(AST)、总胆红素(TBIL)、肿瘤坏死因子(TNF-α)、干扰素(IFN-γ)等指标2组治疗后均改善（P＜0.05），2组治疗后比较差异显著（P＜0.05）。血巨细胞病毒抗体(CMV-IgM)转阴率观察组为42.4%（14/33），对照组为30%（9/30），2组比较无显著差异（P＞0.05）。尿巨细胞病毒DNA(CMV-DNA)转阴率观察组为66.7%（22/33），对照组为33.3%（10/30），2组比较差异显著（P＜0.05）。结论：茵栀黄口服液联合更昔洛韦治疗新生儿CMV肝炎临床疗效显著，CMV-DNA转阴率高。

Abstract:: Objective: To investigate curative effects of YinZhiHuang oral liquid and ganciclovir in treating neonatal cytomegalovirus (CMV) hepatitis. Methods: All 63 patients were randomized into two groups. Both groups accepted the injection of ganciclovir, the observation group were also administered with YinZhiHuang oral liquid, half of one bottle, three times per day. Two weeks were one course of the treatment. The patients in both groups still took other drugs to protect the liver. Results: The indexes of ALT, AST, TBIL, TNF-α, IFN-γ and others were improved after treating in both groups (P＜0.05), the difference was significant (P＜0.05). Blood CMV-IgM negative conversion rate of the observation group was 42.4% (14/33), higher than 30% of the control group (9/30), there was insignificant difference (P＞0.05). Urinary CMV-DNA negative conversion rate of the observation group was 66.7% (22/33), superior to 33.3% of the control group (10/30), the difference was significant (P＜0.05). Conclusion: YinZhiHuang oral liquid and ganciclovir are effective in treating neonatal CMV hepatitis with high CMV-DNA negative conversion rate.